Boston Scientific Corporation $BSX Shares Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd lifted its holdings in Boston Scientific Corporation (NYSE:BSX) by 148.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,120,331 shares of the medical equipment provider’s stock after buying an additional 670,060 shares during the quarter. Boston Scientific accounts for 0.9% of Y Intercept Hong Kong Ltd’s portfolio, making the stock its 4th biggest holding. Y Intercept Hong Kong Ltd owned 0.08% of Boston Scientific worth $47,816,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of BSX. Broadway Wealth Solutions Inc. purchased a new position in shares of Boston Scientific in the 2nd quarter valued at about $294,000. Allen Mooney & Barnes Investment Advisors LLC purchased a new stake in Boston Scientific during the second quarter worth about $318,000. Northside Capital Management LLC grew its position in Boston Scientific by 44.2% during the second quarter. Northside Capital Management LLC now owns 160,366 shares of the medical equipment provider’s stock worth $6,844,000 after buying an additional 49,189 shares during the period. Family Wealth Partners LLC purchased a new position in Boston Scientific in the second quarter valued at about $224,000. Finally, Tema ETFs LLC lifted its position in shares of Boston Scientific by 16.6% during the 2nd quarter. Tema ETFs LLC now owns 45,794 shares of the medical equipment provider’s stock valued at $1,954,000 after acquiring an additional 6,522 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney bought 186,240 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This trade represents a 13.27% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David C. Habiger bought 2,100 shares of Boston Scientific stock in a transaction that occurred on Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director directly owned 17,160 shares of the company’s stock, valued at $816,644.40. This trade represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired 204,322 shares of company stock worth $9,939,221 in the last three months. Company insiders own 0.34% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX opened at $51.40 on Thursday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The company has a market capitalization of $74.49 billion, a price-to-earnings ratio of 20.81, a PEG ratio of 1.12 and a beta of 0.56. The company’s 50 day simple moving average is $45.94 and its 200 day simple moving average is $59.69. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. Boston Scientific’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its Board of Directors has approved a stock repurchase program on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

BSX has been the topic of several research analyst reports. Jefferies Financial Group decreased their price target on Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, June 24th. Raymond James Financial reaffirmed an “outperform” rating and set a $57.00 price objective on shares of Boston Scientific in a report on Thursday, July 30th. Needham & Company LLC decreased their target price on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research report on Wednesday, July 8th. Daiwa Securities Group cut Boston Scientific from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Finally, Citigroup cut their price target on Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.